Ulcerative Colitis

Coverage of the United European Gastroenterology virtual conference made up the top stories in gastroenterology last week.

A recent study showed that Entyvio was associated with higher rates of ulcerative colitis remission than anti-TNF agents. It was the top story in gastroenterology last week.

In this exclusive video, William Sandborn, MD, from the University of California, San Diego, discusses research presented at UEG Week Virtual that explored the safety and efficacy of Zeposia in ulcerative colitis.

Phase 2 data support the safety and efficacy of mirikizumab in patients with Crohn’s disease, according to results presented at UEG Week.

The interim analysis of subcutaneous Entyvio demonstrates the treatment is safe and effective for long-term maintenance of ulcerative colitis, according to results presented at UEG Week.

Patients with ulcerative colitis who received Entyvio in routine practice experienced higher rates of remission than those treated with anti-TNF agents, according to study results.

Risk for developing inflammatory bowel disease was increased among first-degree relatives of individuals who already had the disease, according to study results.

The Cleveland Clinic has appointed colorectal surgeon Conor Delaney, MD, PhD, as the new CEO and president of the institution’s Florida region. It was the top story in gastroenterology last week.

Patient preference favoring treatment discontinuation was improved during treatment with Entyvio or Stelara compared with anti-TNF therapy in patients with inflammatory bowel disease, according to study results.

High expression of ACE2 and TMPRSS2 in the small intestines may support gastrointestinal-correlated replication of SARS-COV-2, according to a study published in Gastroenterology.